Alkermes plc Stock
Price
Target price
?
?
-0.750%
-0.28
-0.750%
€38.07
09:31 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
The price for the Alkermes plc stock decreased slightly today. Compared to yesterday there is a change of -€0.280 (-0.750%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Alkermes plc.
With a target price of 38 € there is a slightly positive potential of 2.7% for Alkermes plc compared to the current price of 37.0 €.
Pros and Cons of Alkermes plc in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -0.750% | 7.552% | 26.512% | 33.577% | 55.085% | 33.577% | 94.681% |
| Icon plc | 6.010% | 11.815% | 37.432% | 7.519% | -15.102% | -36.419% | - |
| United Therapeutics | -0.820% | -2.300% | -5.168% | 66.056% | 10.367% | 132.544% | 225.241% |
| Ligand Pharmaceuticals | 2.970% | 0.990% | 4.082% | 126.667% | 22.892% | 193.525% | 120.112% |
Comments
Alkermes (ALKS) had its price target raised by Robert W. Baird from $45.00 to $48.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Wells Fargo & Company from $43.00 to $44.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for ALKS provided by MarketBeat